Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi;Importancia clínica de los mecanismos de resistencia de los hongos filamentosos a los antifúngicos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue 10, 2002, Pages 523-530

  Mellado, Emilia ^a,b   Cuenca Estrella, Manuel ^a   Rodríguez Tudela, Juan Luis ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal drugs; Filamentous fungi; Resistance mechanisms

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; HEALTH SURVEY; MYCOSIS; PATHOGENICITY; REVIEW; SPECIES DIFFERENTIATION; STRAIN DIFFERENCE;

EID: 0036901988     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0213-005x(02)72856-5     Document Type: Review

References (40)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
2. Singh N. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6.
3. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-805.
4. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
5. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalisations in the United States. Clin Infect Dis 2000;31:1524-8.
6. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: An update. Eur J Clin Microbiol Infect Dis 2002;21:161-72.
7. Latgé JP. Aspergillus fumigatus and Aspergillosis. Clinical Microbiol Rev 1999;12:310-50.
8. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002;46:556-7.
9. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: An alternative hypothesis. Clin Infect Dis 2002;34:1281-3.
10. Hof H. Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother 2001;45:2987-90.
11. a serie. n.° 68: p. 3651-3660.
12. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17.
13. Groll AH, Walsh TJ. Caspofungin: Pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001;10:1545-58.
14. Denning DW. Echinocandins: A new class of antifungal. J Antimicrob Chemother 2002;49:889-91.
15. Te Dorsthorst DT, Verweij PE, Meis JF, Punt NC, Mouton JW. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-suseeptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother 2002;46:702-7.
16. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility. Testing of Filamentous Fungi: Proposed Standard. Document M38-P, NCCLS. Villanova: 1998.
17. Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000;45:85-93.
18. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997;40:401-14.
19. Dannaoui E, Borel E, Persat F, Monier MF, Piens MA. In vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EGBA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J Med Microbiol 1999;48:1087-93.
20. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1364-8.
21. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired Resistance to Itraconazole. Scand J Infect Dis 1997;29:509-12.
22. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001;47:333-40.
23. Espinel-Ingroff A. Clinical utility of in vitro antifungal susceptibility testing. Rev Esp Quimioter 2000;13:161-6.
24. White TC, Marr KA, Bowden RA. Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin Microbiol Rev 1998;11:382-402.
25. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002;8:76-81.
26. Sanglard D. Clinical relevance of mechanisms of antifungal drug resistance in yeast. Enf Infecc Microbiol Clin 2002. En prensa.
27. Manavathu EK, Alangaden GJ, Chandrasekar PH. In vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus. J Antimicrob Chemother 1998;41:615-9.
28. Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol 1999;43:1017-25.
29. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-44.
30. Sanglard D, Odds FC, Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis 2002;2:73-85.
31. Hollomon DW. Resistance to azole fungicides in the field. Biochem Soc Trans 1993;21:1047-51.
32. Andrade AC, Del Sorbo G, Van Nistelrooy JG, Waard MA. The ABC transporter AtrB from Aspergillus nidulans mediates resistance to all major classes of fungicides and some natural toxic compounds. Microbiology 2000;146:1987-97.
33. Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1999;369:1-10.
34. Délye C, Bousset L, Corio-Costet MF. PCR cloning and detection of point mutations in the eburicol 14α-demethylase (CYP51) gene from Erysiphe graminis f. sp. hordei, a "recalcitrant" fungus. Current Genetics 1998;34: 399-403.
35. Délye C, Laigret F, Corio-Costet MF. A mutation in the 14α-demethylase gene of Uncinula necator that correlates with resistance to a sterol biosynthesis inhibitor. Appl Environ Microbiol 1997;63:2966-70.
36. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-α sterol demethylase-related genes (CYP51A and CYP51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001;39:2431-8.
37. Hamamoto H, Hasegawa K, Nakaune R, Lee YJ, Makizumi Y, Akutsu K, Hibi T. Tandem repeat of a transcriptional enhancer upstream of the sterol 14α-demethylase gene (CYP51) in Penicillium digitatum. Appl Environ Microbiol 2000;66:3421-6.
38. Osherov N, Kontoyannis DP, Romans A, May GS Resistant to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14-α-demethylase gene, pdmA. J Antimicrob Chemother 2001;48:75-81.
39. Barbaric D, Shaw PJ. Scedosporium infection in immunocompromised patients: Successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol 2001;37:122-5.
40. Graybill JR. Changing strategies for treatment of systemic mycoses. Braz J Infect Dis 2000;4:47-54.